Association of insurance status with survival in patients with cutaneous T-cell lymphoma

Leuk Lymphoma. 2019 May;60(5):1253-1260. doi: 10.1080/10428194.2018.1520987. Epub 2018 Oct 16.

Abstract

The effect of insurance status on overall survival (OS) of patients with cutaneous T-cell lymphoma (CTCL) is unclear. We identified 11,861 patients from the US National Cancer Data Base diagnosed with CTCL from 2004-2014, of which 6088 had private insurance, 756 had Medicaid, 4536 had Medicare, and 481 are uninsured. Privately insured patients were more likely to present at an early stage (p < .001). On multivariate Cox regression analysis, privately insured patients had significantly longer OS than patients with Medicaid (HR: 1.936, 95% CI: 1.680-2.230, p < .001), Medicare (HR: 1.342, 95% CI: 1.222-1.474, p < .001), or no insurance (HR 1.849, 95% CI: 1.539-2.222, p < .001). The survival advantage of privately insured patients persisted on relative survival and propensity score-matched analyses. In conclusion, privately insured patients were more likely to present at an early stage, and had longer OS than patients who were Medicaid-, Medicare-, or not insured.

Keywords: Cutaneous T-cell lymphoma; National Cancer Database; insurance status; socioeconomic factors; survival analysis.

MeSH terms

  • Databases, Factual
  • Female
  • Humans
  • Insurance Coverage*
  • Insurance, Health*
  • Lymphoma, T-Cell, Cutaneous / epidemiology*
  • Lymphoma, T-Cell, Cutaneous / mortality
  • Male
  • Medicaid
  • Medicare
  • Odds Ratio
  • Proportional Hazards Models
  • Public Health Surveillance
  • United States / epidemiology